5.185

0.00% 0.005

Scynexis Inc (SCYX)

Overview News Price History Option Chain Financials Why SCYX Down? Discussions Forecast Stock Split

Scynexis Inc stock is traded at $5.185, with a volume of 114.08K. It is up +0.00% in the last 24 hours and up +21.31% over the past month. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Previous Close:

$5.18

Open:

$5.2

24h Volume:

114.08K

Relative Volume:

0.86

Market Cap:

$51.34M

Revenue:

$20.34M

Net Income/Loss:

$-24.52M

P/E Ratio:

-1.4499

EPS:

-3.5761

Net Cash Flow:

$-5.92M

1W Performance:

+0.48%

1M Performance:

+21.31%

6M Performance:

-14.80%

1Y Performance:

-22.91%

1-Day Range:

$4.90

$5.52

1-Week Range:

$4.65

$5.52

52-Week Range:

$3.53

$10.48

Scynexis Inc Stock (SCYX) Company Profile

Name

Scynexis Inc

Sector

Healthcare (1089)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

201-884-5485

Address

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Employee

Twitter

@scynexis

Next Earnings Date

2026-08-12

Latest SEC Filings

SCYX's Discussions on Twitter

Compare SCYX vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCYX Scynexis Inc	5.16	51.54M	20.34M	-24.52M	-5.92M	-3.5761
TAK Takeda Pharmaceutical Co Adr	17.36	56.30B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.52	42.85B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.59	42.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.39	30.49B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	506.59	21.43B	3.17B	1.29B	1.01B	27.09

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-21	Initiated	Guggenheim	Buy
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-18	Upgrade	Needham	Hold → Buy
Jun-27-18	Initiated	Maxim Group	Buy
Oct-24-17	Initiated	Guggenheim	Buy
Jul-10-17	Initiated	ROTH Capital	Buy
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform
Oct-20-16	Initiated	H.C. Wainwright	Buy
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy
Aug-09-16	Reiterated	Needham	Buy
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy
Mar-28-16	Initiated	Brean Capital	Buy
Dec-29-15	Initiated	WBB Securities	Speculative Buy
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform
Jun-10-15	Initiated	Needham	Buy
May-29-14	Initiated	Canaccord Genuity	Buy
May-29-14	Initiated	RBC Capital Mkts	Outperform

View All

Scynexis Inc Stock (SCYX) Latest News

Aug 16, 2026

SCYNEXIS (NASDAQ:SCYX) Upgraded at Wall Street Zen - MarketBeat

Aug 16, 2026

Aug 14, 2026

SCYNEXIS (SCYX) investors CVI and Heights disclose 5.9% ownership stake - Stock Titan

Aug 14, 2026

Great Point Partners (SCYX) reports 9.99% beneficial stake in Scynexis - Stock Titan

Aug 14, 2026

Results: SCYNEXIS, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st

Aug 14, 2026

Aug 13, 2026

SCYX Maintained by Guggenheim -- Price Target Raised to $33.00 - GuruFocus

Aug 13, 2026

Guggenheim raises Scynexis stock price target to $33 on drug potential - Investing.com Canada

Aug 13, 2026

Aug 12, 2026

Adage Capital group (SCYX) discloses 1,041,824-share SCYNEXIS stake including warrants - Stock Titan

Aug 12, 2026